Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4681283 | 1.00 | CYP2D6 (0.41) | CYP2D6MEN1RECQLKMT2AIDO1 | |
| SCHEMBL14208065 | 0.79 | DRD2 (0.38) | CYP2D6MEN1RECQLKMT2AADRA1A | |
| SCHEMBL6109896 | 0.79 | DRD2 (0.45) | — | |
| SCHEMBL6109893 | 0.79 | DRD2 (0.45) | — | |
| SCHEMBL14202528 | 0.78 | CYP2D6 (0.38) | CYP2D6MEN1RECQLKMT2AIDO1 | |
| SCHEMBL14458459 | 0.74 | CHRNB2 (0.39) | MEN1KMT2APLAUL3MBTL1CHRNB2 | |
| SCHEMBL5621945 | 0.74 | CHRNB2 (0.39) | MEN1KMT2APLAUL3MBTL1CHRNB2 | |
| SCHEMBL11221034 | 0.74 | DRD2 (0.49) | MEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL11221031 | 0.74 | DRD2 (0.49) | MEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL6107223 | 0.71 | PNMT (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150272962-A1 | METHODS FOR TREATING OR PREVENTING CANCER AND NEURODEGENERATIVE DISEASES | SLOAN KETTERING INST CANCER (US) | 2015-10-01 | — | — | US | disclosed |
| US-20150272962-A1 | METHODS FOR TREATING OR PREVENTING CANCER AND NEURODEGENERATIVE DISEASES | SLOAN KETTERING INST CANCER (US) | 2015-10-01 | — | — | US | disclosed |
| US-9056857-B2 | Methods for treating or preventing cancer and neurodegenerative diseases | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056857-B2 | Methods for treating or preventing cancer and neurodegenerative diseases | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2015-06-16 | — | — | US | disclosed |
| US-20130158017-A1 | METHODS FOR TREATING OR PREVENTING CANCER AND NEURODEGENERATIVE DISEASES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158017-A1 | METHODS FOR TREATING OR PREVENTING CANCER AND NEURODEGENERATIVE DISEASES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158017-A1 | METHODS FOR TREATING OR PREVENTING CANCER AND NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN2 | CYP2D6 4189/4885MEN1 1506/4885RECQL 19/4885 |
| US-20150272962-A1 | METHODS FOR TREATING OR PREVENTING CANCER AND NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN2 | CYP2D6 4189/4885MEN1 1506/4885RECQL 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.